{"gene":"CDKN2C","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1997,"finding":"p18(INK4c) associates with CDK6 upon IL-6 stimulation in B lymphoblastoid cells, suppressing CDK6 activity and thereby inhibiting pRb phosphorylation, leading to cell cycle arrest coupled to terminal B cell differentiation.","method":"Co-immunoprecipitation, Western blot, overexpression in lymphoblastoid cells, flow cytometry","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal association demonstrated by Co-IP, functional overexpression rescue experiment, replicated in multiple cell contexts","pmids":["9052836"],"is_preprint":false},{"year":1998,"finding":"p18(INK4c) and p27(Kip1) mediate two genetically separable pathways to suppress pituitary tumorigenesis; mice lacking both develop pituitary adenomas with near-complete penetrance by 3 months, while single knockouts develop adenomas more slowly, indicating non-redundant collaborative tumor suppression likely through controlling Rb function.","method":"Genetic epistasis — single and double knockout mouse models, histopathology, proliferation assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in mouse models with clear double-mutant phenotypic readout, replicated across multiple groups","pmids":["9744866"],"is_preprint":false},{"year":1999,"finding":"p18(INK4C) and p16(INK4A) share the ankyrin-repeat fold but differ in conformational stability: p18 has a subset of very slowly exchanging amide protons (especially in the fourth ankyrin repeat region) indicating greater kinetic stability than p16 and p15, which correlates with lower aggregation tendency.","method":"NMR (H/2H exchange, heteronuclear NOE), chemical denaturation","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal NMR methods with functional relevance (aggregation), single lab","pmids":["10556039"],"is_preprint":false},{"year":2000,"finding":"p18(INK4c) cooperates with p27(Kip1) to inhibit cyclin E-CDK2 and CDK4/6 in progestin-mediated cell cycle arrest: p27 directly inhibits cyclin E-CDK2 whereas p18 binds CDK4/CDK6 and, through redistribution of CDK inhibitor complexes, secondarily reduces cyclin E-CDK2 activity.","method":"In vitro kinase assay with recombinant His6-p27 and recombinant p18(INK4c), co-immunoprecipitation, gel filtration chromatography, Western blot","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with recombinant proteins plus in-cell validation by Co-IP, single lab with multiple orthogonal methods","pmids":["10713180"],"is_preprint":false},{"year":2001,"finding":"Combined loss of p18(Ink4c) and p19(Ink4d) in male mice causes infertility by impairing mitotic exit of spermatogonia and blocking meiotic maturation of spermatocytes; loss of p18 alone causes Leydig cell hyperplasia with reduced testosterone production independent of LH levels.","method":"Single and double knockout mouse genetics, histopathology, hormone assays (LH, FSH, testosterone), cell cycle analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — double-mutant genetic epistasis with defined cellular phenotype and hormonal readouts, clear loss-of-function design","pmids":["11287627"],"is_preprint":false},{"year":2002,"finding":"p18(INK4c) is required within B cells for terminal plasma cell differentiation and cell cycle arrest; p18-deficient mice show B cell hyperproliferation in germinal centers despite normal class switch, hypermutation, and plasmacytoid differentiation, but severely reduced antibody secretion, placing p18 as a requisite CDK6 inhibitor for functional plasma cell generation.","method":"Conditional/germline knockout mouse model, immunization, ELISA for antibody titers, histology, flow cytometry","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout with multiple cellular and functional readouts; replicates and extends the earlier IL-6/B-cell finding","pmids":["12196289"],"is_preprint":false},{"year":2003,"finding":"p18(INK4c) upregulation by STI571 is required for G1 arrest in ETV6/ARG-expressing leukemia cells; antisense knockdown of Ink4c abrogates STI571-induced growth inhibition, demonstrating that p18 is a downstream effector of ARG kinase suppression.","method":"Antisense oligonucleotide knockdown, cell cycle analysis (flow cytometry), Western blot, cell fractionation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — antisense knockdown with direct functional rescue, single lab, single cell line","pmids":["12821941"],"is_preprint":false},{"year":2003,"finding":"p18(INK4c) collaborates with p21(CIP1) to control G1 timing and with p27(KIP1) to limit hepatocyte DNA synthesis after partial hepatectomy; double knockouts of p18/p21 show earlier CDK activation and earlier G1 exit, while p18/p27 double knockouts show elevated hepatocyte proliferation at 48 hours.","method":"Single and double knockout mouse models, partial hepatectomy, BrdU/PCNA labeling, Western blot for cell cycle proteins","journal":"Hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — double-mutant epistasis with defined cellular readouts, single lab","pmids":["12668976"],"is_preprint":false},{"year":2004,"finding":"In p18(INK4c)-positive hepatocellular carcinomas, p18 preferentially associates with CDK4 rather than CDK6, leading to reduced CDK4 kinase activity and less pRb phosphorylation at Ser780 compared with p18-negative tumors.","method":"Co-immunoprecipitation, in vitro CDK4/CDK6 kinase assay, Western blot with phospho-Rb antibody, immunohistochemistry","journal":"Hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP combined with kinase activity assay in tumor tissue, single lab","pmids":["15349907"],"is_preprint":false},{"year":2004,"finding":"PKC activation by TPA suppresses p18(INK4c) expression at the promoter level in an AP-1-independent manner, and siRNA knockdown of p18 enhances cancer cell growth, demonstrating that p18 is a critical PKC-regulated growth-inhibitory target.","method":"siRNA knockdown, promoter reporter assays, PKC inhibitor (Ro 31-8425), dominant-negative c-Jun expression, cell growth assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA plus pharmacological inhibition plus promoter assay, single lab, multiple orthogonal methods","pmids":["15107819"],"is_preprint":false},{"year":2005,"finding":"Ink4c is haploinsufficient for tumor suppression when combined with Patched (Ptc1) heterozygosity; tumors in Ink4c+/-/Ptc1+/- mice retain wild-type Ink4c but lose wild-type Ptc1, and methylation of INK4C is found in 4/23 human medulloblastomas with absent p18 protein in 14/73 cases, placing Ink4c in the Shh pathway for cerebellar granule cell cycle exit.","method":"Compound heterozygous mouse genetics, LOH analysis, methylation analysis, immunohistochemistry, in situ hybridization","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with allele-specific LOH analysis, multiple orthogonal methods including human tumor validation","pmids":["16260494"],"is_preprint":false},{"year":2005,"finding":"Loss of p18(INK4c) enhances long-term hematopoietic stem cell self-renewal and engraftment over serial transplants; p18-null HSCs resist exhaustion and maintain multilineage potential for >3 years of serial transfers, with effects shown to antagonize p21-driven senescence at the stem cell level.","method":"Serial bone marrow transplantation, competitive repopulation assay, flow cytometry, long-term culture","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — rigorous long-term in vivo functional assay over 3+ years, multiple rounds of transplantation","pmids":["16234365"],"is_preprint":false},{"year":2006,"finding":"MEN2A-specific RET(C634R) simultaneously represses p18/Ink4c and p27 mRNA levels while elevating cyclin D1, requiring functional MAPK signaling; RET2A-dependent p18 repression alone is sufficient to increase proliferation, and MEN2A adrenal tumors recapitulate this expression profile in vivo.","method":"Inducible RET2A expression, RT-PCR, Western blot, MEK inhibitor treatment, cyclin D1/p18/p27 quantification in primary tumors","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible system with pharmacological pathway dissection and in vivo tumor validation, single lab","pmids":["16953232"],"is_preprint":false},{"year":2006,"finding":"p18(Ink4c) and Pten constrain a positive regulatory loop: deletion of p18 (or CDK4 overexpression, or Rb inactivation) activates Akt/PKB, but this is recessive to PTEN reduction, indicating that CDK-dependent Rb pathway outputs feed back to the PI3K/Akt pathway.","method":"Double-mutant mouse models (p18-/-, Pten+/-), Western blot for phospho-Akt, tumor analysis, LOH at Pten locus","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with biochemical readout of Akt activation, single lab","pmids":["16738322"],"is_preprint":false},{"year":2008,"finding":"p18(Ink4c) protein stability is regulated by polyubiquitination at preferred lysines K46 and K112; binding to CDK4 or CDK6 (active or inactive) inhibits polyubiquitination and stabilizes p18, while cyclin D1 competes with p18 for CDK binding and accelerates p18 degradation. Substitution of multiple lysines triggers misfolding and accelerates degradation.","method":"In vitro ubiquitination assay, site-directed mutagenesis (lysine-to-arginine substitutions), co-expression with CDKs and cyclin D1, half-life measurement","journal":"Cell cycle","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro biochemical reconstitution combined with mutagenesis and half-life measurements; multiple mechanistic conclusions supported","pmids":["19029828"],"is_preprint":false},{"year":2008,"finding":"Lentiviral reconstitution of p18(INK4c) at physiologic levels in p18-deficient GBM cells induces senescence-like G1 arrest, while p18-proficient GBM cells are unaffected, establishing p18 as a functional tumor suppressor whose loss drives CDK-mediated cell cycle progression in GBM.","method":"Lentiviral reconstitution, cell cycle analysis (flow cytometry), immunohistochemistry on primary GBM tumors","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reconstitution experiment with isogenic p18-deficient vs. -proficient controls, single lab","pmids":["18381405"],"is_preprint":false},{"year":2008,"finding":"NaBu-induced p18(INK4c) upregulation requires intact Sp1 binding sites in the p18 promoter; NaBu causes histone H3/H4 hyperacetylation at the endogenous p18 promoter and enhanced Sp1 binding in vivo, and overexpression of p18 alone induces G0/G1 arrest and partial erythroid differentiation in K562 cells.","method":"Promoter reporter assays with Sp1 cluster mutations, chromatin immunoprecipitation (ChIP), flow cytometry, overexpression","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus promoter mutagenesis plus functional overexpression, single lab","pmids":["18642058"],"is_preprint":false},{"year":2009,"finding":"GATA3 directly binds to and represses INK4C transcription; loss of p18(INK4c) in mice causes spontaneous ER-positive luminal mammary tumors, and GATA3-driven expansion of luminal progenitor cells is mechanistically linked to p18 repression.","method":"ChIP demonstrating GATA3 binding at INK4C locus, transgenic/knockout mouse models, gene expression analysis, luciferase reporter","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct ChIP plus loss-of-function mouse genetics plus mechanistic reporter assay, consistent with independent in vitro and in vivo data","pmids":["19411068"],"is_preprint":false},{"year":2010,"finding":"RET2A signaling induces N-Myc via MAPK; N-Myc then binds an initiator consensus element in the p18(Ink4c) promoter to repress p18 transcription; loss of N-Myc induction prevents RET2A-mediated p18 repression and hyperproliferation.","method":"Promoter ChIP for N-Myc binding, siRNA/dominant-negative N-Myc, RT-PCR, promoter reporter assay, MEK inhibitor","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus promoter reporter plus knockdown, single lab","pmids":["21112821"],"is_preprint":false},{"year":2011,"finding":"A reduced-expression NZB allele of Cdkn2c (due to an SNP in the promoter) causes defective G1 arrest in splenic B cells and increased proliferation of peritoneal B1a cells, mapping CDKN2C as the functional gene within the Sle2c1 lupus susceptibility locus responsible for B1a cell expansion.","method":"Genetic mapping, promoter SNP identification, B cell proliferation assay, cell cycle analysis, co-segregation analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic mapping combined with functional cell cycle assay, single lab","pmids":["21543644"],"is_preprint":false},{"year":2012,"finding":"BRAF(V600E)/NRAS(G12D)-driven MAPK signaling promotes G1 melanoma cell proliferation through AP-1 (c-Jun)-mediated transcriptional repression of CDKN2C; dominant-negative AP-1 restores CDKN2C expression and pharmacological CDK2/4 inhibition augments effects of BRAF/MEK inhibitors in vitro and in vivo.","method":"Dominant-negative c-Jun expression, Western blot, flow cytometry, cell proliferation assay, xenograft tumor model","journal":"Journal of the National Cancer Institute","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant-negative approach with in vitro and xenograft validation, single lab","pmids":["22997239"],"is_preprint":false},{"year":2013,"finding":"Gata3 associates with Ruvbl2 and, as a complex, directly binds the Cdkn2c locus to repress its transcription in Th2 cells; Gata3-dependent repression of Cdkn2c facilitates Th2 cell proliferation, and knockdown of Cdkn2c rescues the proliferation defect in Gata3-deficient Th2 cells.","method":"Co-immunoprecipitation of Gata3/Ruvbl2 complex, ChIP at Cdkn2c locus, Ruvbl2 knockdown, Cdkn2c knockdown rescue experiment, airway inflammation model","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus ChIP plus epistatic knockdown rescue, multiple orthogonal methods in one study","pmids":["24167278"],"is_preprint":false},{"year":2013,"finding":"p18(Ink4c) interacts with CDK4 in adult human pancreatic β-cells (detected by co-immunoprecipitation), and p18 protein localizes predominantly to the cytosol while p27(Kip1) localizes to nuclei, both contributing to maintenance of β-cell quiescence.","method":"Co-immunoprecipitation, immunofluorescence/confocal microscopy, subcellular fractionation, BrdU incorporation assay","journal":"Islets","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP and confocal localization, functional BrdU assay, single lab, single paper","pmids":["23896637"],"is_preprint":false},{"year":2015,"finding":"Small-molecule inhibitors of p18(INK4c) identified by in silico structure-based screening specifically block p18 activity and promote ex vivo expansion of functional murine and human hematopoietic stem cells; lead compound XIE18-6 analogue (compound 40) expands HSCs with ED50 = 5.21 nM without cytotoxicity.","method":"In silico 3D screening based on p18 structure, SAR synthesis, HSC expansion assay (long-term culture), single-cell analysis, competitive repopulation in mice","journal":"Nature communications / Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — structure-based inhibitor design with in vitro and in vivo HSC functional validation, two independent publications from same group","pmids":["25692908","26681454"],"is_preprint":false},{"year":2016,"finding":"p18(INK4c) functions as a cell-intrinsic inhibitor of gammaherpesvirus reactivation from latency; the viral cyclin specifically bypasses p18 to enable reactivation, and genetic ablation of p18 alone is sufficient to render the viral cyclin dispensable for reactivation from latency.","method":"Knockout mouse genetics (p18-/-, p27-/- single and double knockouts), recombinant virus with p18 knock-in (p18KI), viral reactivation assay, BAFF cytokine treatment","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with recombinant virus knock-in, multiple genetic backgrounds tested, functional viral reactivation readout","pmids":["26292318","29298882"],"is_preprint":false},{"year":2016,"finding":"p18(INK4c) and p57(Kip2) nuclear localization is associated with antiproliferative TKI activity in CML cells; TKI treatment reduces nuclear p18 in CML leukemic stem cells, suggesting that subcellular redistribution of p18 contributes to quiescence maintenance after TKI treatment.","method":"Subcellular fractionation, immunofluorescence, cell cycle analysis in CML cell lines and primary CD34+CD38-lin- LSCs and HSCs","journal":"Cell cycle","confidence":"Low","confidence_rationale":"Tier 3 / Weak — localization by immunofluorescence/fractionation without direct functional manipulation of p18 localization, single lab","pmids":["26985855"],"is_preprint":false},{"year":2016,"finding":"PML/RARα directly binds the CDKN2C promoter and represses its transcription in a dose-dependent manner; all-trans retinoic acid releases PML/RARα from chromatin and restores CDKN2C expression; ectopic CDKN2C expression induces G0/G1 arrest and partial differentiation in APL NB4 cells.","method":"Chromatin immunoprecipitation (ChIP-qPCR), luciferase reporter assay, ATRA treatment, CDKN2C overexpression, flow cytometry","journal":"Frontiers of medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP combined with promoter reporter and functional overexpression, single lab","pmids":["27888400"],"is_preprint":false},{"year":2018,"finding":"SETDB2 (a protein lysine methyltransferase) silences CDKN2C through histone H3K9 trimethylation at its locus; SETDB2 is a direct E2A-PBX1 target gene, establishing an oncogenic axis E2A-PBX1→SETDB2→H3K9me3 at CDKN2C→CDKN2C repression in pre-BCR+ ALL.","method":"ChIP for H3K9me3 at CDKN2C locus, SETDB2 knockdown, E2A-PBX1 ChIP, gene expression analysis, in vitro and in vivo leukemia maintenance assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP demonstrating H3K9me3 enrichment plus epistatic knockdown experiments with in vivo validation, multiple orthogonal methods","pmids":["29694893"],"is_preprint":false},{"year":2020,"finding":"CDKN2C induces G1 arrest by inhibiting CDK4/6, which is required for efficient HBV replication; CDKN2C is overexpressed in highly permissive hepatocytes and HBV-infected patients, and its loss reduces viral transcription enhancer activity, identifying CDKN2C-dependent G1 arrest as a proviral mechanism.","method":"Genome-wide gain-of-function screen, validation in primary human hepatocytes, gene knockdown/overexpression, viral replication assay, transcription enhancer reporter","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional screen validation in primary hepatocytes with mechanistic reporter assay, single lab","pmids":["32483149"],"is_preprint":false},{"year":2020,"finding":"LINC00673 lncRNA represses CDKN2C expression through EZH2-mediated H3K27 trimethylation at the CDKN2C promoter; EZH2 inhibition or LINC00673 knockdown increases CDKN2C protein, and CDKN2C depletion restores G1/S progression in cells with reduced LINC00673.","method":"ChIP for H3K27me3 at CDKN2C promoter, EZH2 inhibitor treatment, siRNA knockdown, Western blot, flow cytometry","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus pharmacological inhibition plus epistatic knockdown, single lab","pmids":["33014799"],"is_preprint":false},{"year":2022,"finding":"p18INK4C protects CDK6 from degradation by the CDK6-specific PROTAC BSJ-03-123: CDK6 complexes containing p18INK4C (or p16INK4A) are shielded from PROTAC-mediated degradation; elevated INK4 levels in KMT2A-MLLT3+ AML cells correlate with resistance to CDK6 degradation.","method":"CDK6 degrader (PROTAC BSJ-03-123) treatment, Western blot, co-immunoprecipitation, proliferation assay in AML cell lines","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP showing complex protection from degradation with pharmacological PROTAC, single lab","pmids":["35326705"],"is_preprint":false},{"year":2023,"finding":"CBX8 directly binds to the CDKN2C promoter and establishes H2AK119 ubiquitination to repress CDKN2C transcription in lung adenocarcinoma; CBX8 depletion reduces H2AK119ub enrichment at the CDKN2C promoter, and CDKN2C knockdown rescues the growth/invasion suppression caused by CBX8 depletion.","method":"ChIP assay for CBX8 binding and H2AK119ub at CDKN2C promoter, CBX8 knockdown/overexpression, CDKN2C knockdown rescue experiment, RNA sequencing","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus epistatic rescue experiment, single lab","pmids":["37733753"],"is_preprint":false},{"year":2024,"finding":"CDKN2C overexpression enhances radiosensitivity of osteosarcoma cells by inducing G1 arrest through suppression of CDK4 expression and Thr172 phosphorylation (but not CDK6 or Cyclin D1 expression), leading to reduced pRb Ser807/811 phosphorylation and increased apoptosis (BAX, Caspase-3) when combined with irradiation.","method":"Lentiviral CDKN2C overexpression, Western blot for CDK4 phosphorylation and pRb phosphorylation, flow cytometry cell cycle analysis, xenograft mouse model, apoptosis assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — overexpression with mechanistic Western blot readouts and in vivo validation, single lab","pmids":["39426133"],"is_preprint":false},{"year":2024,"finding":"Oxidative modification of miR-30c at positions 4 and 5 (G→O8G, producing 4,5-oxo-miR-30c) causes mismatch recognition of CDKN2C mRNA, reducing CDKN2C protein levels and promoting cardiac fibroblast proliferation; unmodified miR-30c does not target CDKN2C in this manner.","method":"Luciferase reporter assay, miRNA immunoprecipitation with O8G antibody, cardiac fibrosis animal models (Ang II, ischemia-reperfusion), overexpression of oxidized miR-30c mimics","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase validation of mismatch targeting plus in vivo animal models, single lab","pmids":["38849466"],"is_preprint":false},{"year":2025,"finding":"RNF149, a RING finger ubiquitin ligase, ubiquitinates CDKN2C protein in head and neck squamous cell carcinoma; RNF149 and CDKN2C show an inverse expression correlation in tissue arrays, and RNF149 knockdown reduces HNSC proliferation while altering CDK inhibitor sensitivity.","method":"Proximity ligation assay, immunoprecipitation, gene knockdown, proliferation/cell cycle assay, 3D assay, tissue array immunohistochemistry","journal":"Anticancer research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — PLA and Co-IP suggest ubiquitination interaction, single lab, no direct ubiquitin transfer assay shown in abstract","pmids":["42049330"],"is_preprint":false}],"current_model":"CDKN2C/p18(INK4c) is an ankyrin-repeat CDK inhibitor that binds CDK4 and CDK6 to prevent their activation by D-type cyclins, thereby maintaining Rb in its hypophosphorylated growth-suppressive state; its stability is controlled by polyubiquitination at K46/K112 that is inhibited by CDK binding and accelerated by competition with cyclin D1, and its transcription is regulated by multiple epigenetic mechanisms including GATA3-direct binding, EZH2-mediated H3K27me3 (via LINC00673), CBX8-mediated H2AK119ub, SETDB2-mediated H3K9me3 (downstream of E2A-PBX1), PML/RARα direct promoter binding, N-Myc (downstream of RET/MAPK), and Sp1 acetylation-dependent activation, placing it as a nodal tumor suppressor required for plasma cell differentiation, hematopoietic stem cell self-renewal restraint, spermatogenesis, mammary luminal progenitor control, and cell-intrinsic suppression of gammaherpesvirus reactivation."},"narrative":{"mechanistic_narrative":"CDKN2C/p18(INK4c) is an ankyrin-repeat CDK inhibitor that enforces G1 cell cycle exit by binding CDK4 and CDK6 to suppress their kinase activity, thereby maintaining Rb in its hypophosphorylated, growth-suppressive state across diverse differentiating tissues [PMID:9052836, PMID:15349907, PMID:39426133]. It engages CDK6 upon IL-6 stimulation to couple cell cycle arrest to terminal B cell/plasma cell differentiation [PMID:9052836, PMID:12196289], and cooperates with the Cip/Kip inhibitors p27 and p21 in genetically separable pathways that restrain proliferation in the pituitary, liver, and other tissues, in part by redistributing CDK-inhibitor complexes to secondarily lower cyclin E-CDK2 activity [PMID:9744866, PMID:10713180, PMID:12668976]. Through this CDK4/6-Rb axis p18 acts as a nodal tumor suppressor whose loss or repression drives proliferation and tumorigenesis: it restrains hematopoietic stem cell self-renewal [PMID:16234365], limits mammary luminal progenitor expansion [PMID:19411068], and is haploinsufficient within the Shh/Patched pathway in medulloblastoma [PMID:16260494]. Its dosage is set at two levels. Post-translationally, p18 stability is governed by polyubiquitination at preferred lysines K46 and K112; CDK4/6 binding shields p18 from ubiquitination and stabilizes it, while cyclin D1 competes for CDK binding and accelerates p18 turnover [PMID:19029828]. Transcriptionally, p18 is repressed by a convergent set of factors and chromatin modifiers, including direct GATA3 binding (in complex with Ruvbl2) [PMID:19411068, PMID:24167278], oncogenic MAPK-driven repression via AP-1/c-Jun and N-Myc [PMID:21112821, PMID:22997239], PML/RARα at the promoter [PMID:27888400], and Polycomb/heterochromatin marks deposited by EZH2 (H3K27me3, via LINC00673), CBX8 (H2AK119ub), and SETDB2 (H3K9me3, downstream of E2A-PBX1) [PMID:29694893, PMID:33014799, PMID:37733753]. p18 also functions as a cell-intrinsic restrictor of gammaherpesvirus reactivation, an activity specifically bypassed by the viral cyclin [PMID:26292318, PMID:29298882].","teleology":[{"year":1997,"claim":"Established that p18(INK4c) physically engages CDK6 and links cytokine signaling to cell cycle arrest, defining its core molecular activity in differentiation.","evidence":"Co-IP and overexpression in IL-6-stimulated B lymphoblastoid cells with pRb phosphorylation readout","pmids":["9052836"],"confidence":"High","gaps":["Did not distinguish CDK6 versus CDK4 preference in other contexts","Endogenous regulation of p18 induction by IL-6 not mapped"]},{"year":1998,"claim":"Demonstrated that p18 suppresses tumorigenesis through a pathway genetically separable from p27, showing it is a non-redundant in vivo tumor suppressor.","evidence":"Single and double knockout mouse genetics with pituitary adenoma histopathology","pmids":["9744866"],"confidence":"High","gaps":["Molecular basis of the p18/p27 division of labor at the CDK level not fully resolved here"]},{"year":1999,"claim":"Resolved how p18 differs biophysically from related INK4 proteins, showing greater kinetic stability of its ankyrin-repeat fold.","evidence":"NMR H/2H exchange and chemical denaturation of p18 versus p16/p15","pmids":["10556039"],"confidence":"High","gaps":["Conformational stability not directly tied to CDK-binding affinity or in-cell function"]},{"year":2000,"claim":"Clarified that p18 cooperates with p27 not by directly inhibiting CDK2 but by redistributing inhibitor complexes, explaining secondary suppression of cyclin E-CDK2.","evidence":"In vitro kinase assays with recombinant proteins, Co-IP, and gel filtration in progestin-arrested cells","pmids":["10713180"],"confidence":"High","gaps":["Quantitative stoichiometry of complex redistribution in vivo not established"]},{"year":2001,"claim":"Extended p18 function to germ cell and Leydig cell proliferation control, showing tissue-specific requirements in spermatogenesis.","evidence":"Single/double p18/p19 knockout mouse genetics with hormone assays and cell cycle analysis","pmids":["11287627"],"confidence":"High","gaps":["CDK partner mediating the spermatogonial and Leydig phenotypes not pinpointed"]},{"year":2002,"claim":"Showed p18 is required cell-intrinsically in B cells for terminal plasma cell differentiation and antibody secretion, cementing its differentiation-arrest role.","evidence":"Knockout mouse immunization with ELISA antibody titers, histology, flow cytometry","pmids":["12196289"],"confidence":"High","gaps":["Transcriptional trigger of p18 during plasma cell commitment not defined"]},{"year":2003,"claim":"Identified p18 as a downstream effector of oncogenic kinase inhibition and as a collaborator with Cip/Kip inhibitors in regenerative proliferation, broadening its signaling context.","evidence":"Antisense knockdown in ETV6/ARG leukemia cells; p18/p21 and p18/p27 double-knockout partial hepatectomy models","pmids":["12821941","12668976"],"confidence":"Medium","gaps":["Single-cell-line antisense without reciprocal validation","Direct vs indirect link between ARG kinase and p18 transcription unresolved"]},{"year":2004,"claim":"Established context-dependent CDK partner choice and the first promoter-level repression mechanism, showing p18 preferentially binds CDK4 in HCC and is suppressed by PKC signaling.","evidence":"Co-IP plus CDK4/CDK6 kinase assays in HCC tumors; siRNA, promoter reporters, and PKC inhibition in cancer cells","pmids":["15349907","15107819"],"confidence":"Medium","gaps":["The PKC-responsive promoter element/transcription factor not identified","AP-1-independence mechanism left open"]},{"year":2005,"claim":"Defined p18 as a dosage-sensitive tumor suppressor within the Shh pathway and as a restraint on hematopoietic stem cell self-renewal, revealing stem/progenitor roles.","evidence":"Ink4c+/-/Ptc1+/- compound genetics with LOH and human medulloblastoma methylation; serial bone marrow transplantation of p18-null HSCs","pmids":["16260494","16234365"],"confidence":"High","gaps":["How p18 intersects Shh signaling molecularly not detailed","Mechanism of p18/p21 antagonism in HSC senescence not resolved"]},{"year":2006,"claim":"Connected oncogenic RET/MAPK and Rb-pathway output to p18 regulation, showing p18 repression is both an effector of and feedback node for proliferative signaling.","evidence":"Inducible RET2A with MEK inhibition and tumor profiling; p18/Pten double-mutant mice with phospho-Akt readouts","pmids":["16953232","16738322"],"confidence":"Medium","gaps":["Direct transcriptional mediator of RET-driven p18 repression not yet identified (resolved later by N-Myc)","Mechanism of Rb-to-Akt feedback indirect"]},{"year":2008,"claim":"Defined the post-translational control of p18 abundance and its functional sufficiency as a senescence-inducing tumor suppressor, and identified an Sp1/acetylation-dependent activation route.","evidence":"In vitro ubiquitination with K-to-R mutagenesis and half-life measurement; lentiviral reconstitution in GBM cells; ChIP and Sp1-site promoter mutagenesis in K562","pmids":["19029828","18381405","18642058"],"confidence":"High","gaps":["Identity of the physiological E3 ligase for K46/K112 ubiquitination not established","Cofactor coupling Sp1 to acetylation not defined"]},{"year":2009,"claim":"Identified GATA3 as a direct transcriptional repressor of INK4C, mechanistically linking luminal progenitor expansion and ER+ mammary tumorigenesis to p18 loss.","evidence":"ChIP, luciferase reporter, and loss-of-function mouse genetics in mammary tissue","pmids":["19411068"],"confidence":"High","gaps":["Cofactor requirement for GATA3 repression not yet defined (later linked to Ruvbl2)"]},{"year":2010,"claim":"Pinpointed N-Myc as the direct MAPK-induced repressor at the p18 promoter, completing the RET2A→MAPK→N-Myc→p18 repression axis.","evidence":"N-Myc promoter ChIP, dominant-negative/knockdown, reporter assays, and MEK inhibition","pmids":["21112821"],"confidence":"Medium","gaps":["Single-lab promoter study; generality across N-Myc-driven tumors untested"]},{"year":2011,"claim":"Showed a hypomorphic Cdkn2c promoter allele drives autoimmune B1a cell expansion, establishing p18 dosage as a disease-relevant determinant of B cell proliferation.","evidence":"Genetic mapping, promoter SNP identification, and B cell cell-cycle assays in the lupus Sle2c1 locus","pmids":["21543644"],"confidence":"Medium","gaps":["Mechanism by which the promoter SNP lowers expression not detailed"]},{"year":2012,"claim":"Demonstrated AP-1/c-Jun-mediated CDKN2C repression downstream of BRAF/NRAS as a therapeutic vulnerability, supporting combined CDK and MAPK inhibition.","evidence":"Dominant-negative c-Jun, proliferation assays, and xenografts in melanoma","pmids":["22997239"],"confidence":"Medium","gaps":["Direct AP-1 binding at the CDKN2C promoter not shown here"]},{"year":2013,"claim":"Revealed the GATA3-Ruvbl2 complex as the repressive machinery at Cdkn2c and extended this control to Th2 proliferation, and localized p18-CDK4 interaction to the cytosol in quiescent beta-cells.","evidence":"Gata3/Ruvbl2 Co-IP, ChIP, and Cdkn2c-knockdown rescue in Th2 cells; Co-IP and confocal fractionation in human beta-cells","pmids":["24167278","23896637"],"confidence":"High","gaps":["Functional significance of cytosolic p18 localization not directly tested","Whether GATA3-Ruvbl2 operates identically in mammary tissue untested"]},{"year":2015,"claim":"Provided pharmacological proof that inhibiting p18 expands functional HSCs, validating p18 as a druggable restraint on stem cell self-renewal.","evidence":"Structure-based in silico screening, SAR, HSC expansion assays, and competitive repopulation","pmids":["25692908","26681454"],"confidence":"Medium","gaps":["Direct binding mode of inhibitors to p18 and on-target specificity in vivo not fully resolved"]},{"year":2016,"claim":"Established p18 as a cell-intrinsic restrictor of gammaherpesvirus reactivation, with a viral cyclin specifically bypassing it, and identified additional epigenetic repressors and a localization correlate in leukemia.","evidence":"p18 knockout/knock-in recombinant virus reactivation assays; PML/RARα ChIP and reporter with ATRA in APL; p18 immunofluorescence/fractionation in CML LSCs","pmids":["26292318","29298882","27888400","26985855"],"confidence":"High","gaps":["How p18 restricts reactivation mechanistically beyond CDK inhibition not defined","CML localization study lacks direct functional manipulation"]},{"year":2018,"claim":"Defined the E2A-PBX1→SETDB2→H3K9me3 axis silencing CDKN2C, identifying heterochromatin-mediated repression as a leukemia maintenance mechanism.","evidence":"H3K9me3 and E2A-PBX1 ChIP, SETDB2 knockdown, and in vivo leukemia maintenance assays in pre-BCR+ ALL","pmids":["29694893"],"confidence":"High","gaps":["Whether other INK4 loci are co-regulated by this axis not addressed"]},{"year":2020,"claim":"Expanded the repressive epigenetic repertoire (EZH2/H3K27me3 via LINC00673) and uncovered a proviral role in which CDKN2C-driven G1 arrest supports HBV replication.","evidence":"H3K27me3 ChIP, EZH2 inhibition, siRNA in cancer cells; genome-wide gain-of-function screen and viral replication assays in primary hepatocytes","pmids":["33014799","32483149"],"confidence":"Medium","gaps":["Mechanistic link between G1 arrest and HBV enhancer activity incompletely defined"]},{"year":2022,"claim":"Showed INK4 binding shields CDK6 from targeted degradation, revealing p18 levels as a determinant of CDK6-PROTAC resistance.","evidence":"CDK6 PROTAC treatment, Co-IP, and proliferation assays in AML cell lines","pmids":["35326705"],"confidence":"Medium","gaps":["Structural basis of degrader shielding not resolved"]},{"year":2023,"claim":"Added CBX8/H2AK119ub as a Polycomb repressor of CDKN2C driving lung adenocarcinoma growth, reinforcing the epigenetic-silencing theme.","evidence":"CBX8 and H2AK119ub ChIP, knockdown/overexpression, and CDKN2C-knockdown rescue with RNA-seq","pmids":["37733753"],"confidence":"Medium","gaps":["Interplay among the multiple repressive marks at CDKN2C not integrated"]},{"year":2024,"claim":"Demonstrated CDKN2C confers radiosensitivity via CDK4-Thr172/pRb suppression and identified oxidized miR-30c as a post-transcriptional repressor, broadening the regulatory and therapeutic landscape.","evidence":"Lentiviral overexpression with phospho-CDK4/pRb readouts and xenografts in osteosarcoma; luciferase and O8G miRNA IP in cardiac fibrosis models","pmids":["39426133","38849466"],"confidence":"Medium","gaps":["Whether CDK4-selective effect generalizes beyond osteosarcoma untested","Endogenous prevalence of oxidized miR-30c targeting CDKN2C in human disease unclear"]},{"year":2025,"claim":"Proposed RNF149 as a ubiquitin ligase acting on CDKN2C in HNSC, addressing which E3 controls p18 turnover.","evidence":"Proximity ligation assay, Co-IP, knockdown, and tissue arrays in head and neck squamous carcinoma","pmids":["42049330"],"confidence":"Low","gaps":["No direct ubiquitin transfer assay demonstrating RNF149 catalyzes p18 ubiquitination","Single lab without reciprocal in vivo validation"]},{"year":null,"claim":"The physiological E3 ligase(s) executing the K46/K112 polyubiquitination that sets p18 half-life, and how the many transcriptional/epigenetic repressors are coordinated in a given lineage, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No validated endogenous E3 ligase for K46/K112 ubiquitination","No structural model of the p18-CDK4/6 complex described in the corpus","Combinatorial logic of GATA3, Polycomb, SETDB2, and MAPK-driven repressors not integrated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,3,8,32]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,3,14,30]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[22]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[25]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,3,8,32]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,5,11,17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,10,15,17,20,27,31]}],"complexes":[],"partners":["CDK4","CDK6","CCND1","CDKN1B","GATA3","RUVBL2","RNF149"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P42773","full_name":"Cyclin-dependent kinase 4 inhibitor C","aliases":["Cyclin-dependent kinase 6 inhibitor","p18-INK4c","p18-INK6"],"length_aa":168,"mass_kda":18.1,"function":"Interacts strongly with CDK6, weakly with CDK4. Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/P42773/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CDKN2C","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CDK4","stoichiometry":10.0}],"url":"https://opencell.sf.czbiohub.org/search/CDKN2C","total_profiled":1310},"omim":[{"mim_id":"603369","title":"CYCLIN-DEPENDENT KINASE INHIBITOR 2C; CDKN2C","url":"https://www.omim.org/entry/603369"},{"mim_id":"600927","title":"CYCLIN-DEPENDENT KINASE INHIBITOR 2D; CDKN2D","url":"https://www.omim.org/entry/600927"},{"mim_id":"600778","title":"CYCLIN-DEPENDENT KINASE INHIBITOR 1B; CDKN1B","url":"https://www.omim.org/entry/600778"},{"mim_id":"164840","title":"MYCN PROTOONCOGENE, bHLH TRANSCRIPTION FACTOR; MYCN","url":"https://www.omim.org/entry/164840"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"adipose tissue","ntpm":92.4},{"tissue":"lymphoid tissue","ntpm":89.5}],"url":"https://www.proteinatlas.org/search/CDKN2C"},"hgnc":{"alias_symbol":["INK4C","p18"],"prev_symbol":[]},"alphafold":{"accession":"P42773","domains":[{"cath_id":"1.25.40.20","chopping":"1-62","consensus_level":"medium","plddt":91.7894,"start":1,"end":62},{"cath_id":"1.25.40.20","chopping":"67-163","consensus_level":"medium","plddt":94.8254,"start":67,"end":163}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P42773","model_url":"https://alphafold.ebi.ac.uk/files/AF-P42773-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P42773-F1-predicted_aligned_error_v6.png","plddt_mean":91.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CDKN2C","jax_strain_url":"https://www.jax.org/strain/search?query=CDKN2C"},"sequence":{"accession":"P42773","fasta_url":"https://rest.uniprot.org/uniprotkb/P42773.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P42773/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P42773"}},"corpus_meta":[{"pmid":"9744866","id":"PMC_9744866","title":"CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9744866","citation_count":330,"is_preprint":false},{"pmid":"10358062","id":"PMC_10358062","title":"Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10358062","citation_count":268,"is_preprint":false},{"pmid":"10880462","id":"PMC_10880462","title":"Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10880462","citation_count":225,"is_preprint":false},{"pmid":"11485924","id":"PMC_11485924","title":"Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.","date":"2001","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11485924","citation_count":219,"is_preprint":false},{"pmid":"21994415","id":"PMC_21994415","title":"Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21994415","citation_count":153,"is_preprint":false},{"pmid":"20507346","id":"PMC_20507346","title":"The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes.","date":"2010","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20507346","citation_count":151,"is_preprint":false},{"pmid":"11343236","id":"PMC_11343236","title":"Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.","date":"2001","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11343236","citation_count":148,"is_preprint":false},{"pmid":"9052836","id":"PMC_9052836","title":"Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9052836","citation_count":133,"is_preprint":false},{"pmid":"16260494","id":"PMC_16260494","title":"The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation.","date":"2005","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/16260494","citation_count":131,"is_preprint":false},{"pmid":"16234365","id":"PMC_16234365","title":"Hematopoietic stem cell exhaustion impacted by p18 INK4C and p21 Cip1/Waf1 in opposite manners.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16234365","citation_count":102,"is_preprint":false},{"pmid":"11287627","id":"PMC_11287627","title":"Control of spermatogenesis in mice by the cyclin D-dependent kinase inhibitors p18(Ink4c) and p19(Ink4d).","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11287627","citation_count":94,"is_preprint":false},{"pmid":"18829482","id":"PMC_18829482","title":"Deletions of CDKN2C in multiple myeloma: biological and clinical implications.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18829482","citation_count":88,"is_preprint":false},{"pmid":"12196289","id":"PMC_12196289","title":"CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells.","date":"2002","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12196289","citation_count":87,"is_preprint":false},{"pmid":"11668523","id":"PMC_11668523","title":"A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11668523","citation_count":84,"is_preprint":false},{"pmid":"12556487","id":"PMC_12556487","title":"Haploinsufficiency of p18(INK4c) sensitizes mice to carcinogen-induced tumorigenesis.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12556487","citation_count":83,"is_preprint":false},{"pmid":"19411068","id":"PMC_19411068","title":"CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis.","date":"2009","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/19411068","citation_count":81,"is_preprint":false},{"pmid":"10515227","id":"PMC_10515227","title":"Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors.","date":"1999","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10515227","citation_count":75,"is_preprint":false},{"pmid":"12698196","id":"PMC_12698196","title":"Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells.","date":"2003","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12698196","citation_count":65,"is_preprint":false},{"pmid":"10713180","id":"PMC_10713180","title":"Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10713180","citation_count":64,"is_preprint":false},{"pmid":"8703847","id":"PMC_8703847","title":"Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma.","date":"1996","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8703847","citation_count":63,"is_preprint":false},{"pmid":"14500377","id":"PMC_14500377","title":"Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14500377","citation_count":58,"is_preprint":false},{"pmid":"19916573","id":"PMC_19916573","title":"In silico structural and functional analysis of fragments of the ankyrin repeat protein p18(INK4c).","date":"2010","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/19916573","citation_count":49,"is_preprint":false},{"pmid":"8630967","id":"PMC_8630967","title":"Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas.","date":"1996","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8630967","citation_count":45,"is_preprint":false},{"pmid":"23715670","id":"PMC_23715670","title":"Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas.","date":"2013","source":"Hormones & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23715670","citation_count":44,"is_preprint":false},{"pmid":"18973139","id":"PMC_18973139","title":"Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.","date":"2009","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18973139","citation_count":43,"is_preprint":false},{"pmid":"25692908","id":"PMC_25692908","title":"Small-molecule inhibitors targeting INK4 protein p18(INK4C) enhance ex vivo expansion of haematopoietic stem cells.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25692908","citation_count":43,"is_preprint":false},{"pmid":"11544316","id":"PMC_11544316","title":"An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11544316","citation_count":42,"is_preprint":false},{"pmid":"16738322","id":"PMC_16738322","title":"p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16738322","citation_count":42,"is_preprint":false},{"pmid":"18381405","id":"PMC_18381405","title":"Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18381405","citation_count":42,"is_preprint":false},{"pmid":"27610696","id":"PMC_27610696","title":"Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.","date":"2016","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/27610696","citation_count":40,"is_preprint":false},{"pmid":"20833334","id":"PMC_20833334","title":"MEN-4 and other multiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27(Kip1) and p18(INK4C)) mutations.","date":"2010","source":"Best practice & research. Clinical endocrinology & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20833334","citation_count":39,"is_preprint":false},{"pmid":"15349907","id":"PMC_15349907","title":"Reduced expression of cell cycle regulator p18(INK4C) in human hepatocellular carcinoma.","date":"2004","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15349907","citation_count":39,"is_preprint":false},{"pmid":"9537438","id":"PMC_9537438","title":"Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma.","date":"1998","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/9537438","citation_count":38,"is_preprint":false},{"pmid":"10517502","id":"PMC_10517502","title":"Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas.","date":"1999","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/10517502","citation_count":38,"is_preprint":false},{"pmid":"9724087","id":"PMC_9724087","title":"Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study.","date":"1998","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9724087","citation_count":36,"is_preprint":false},{"pmid":"10556039","id":"PMC_10556039","title":"Tumor suppressor INK4: comparisons of conformational properties between p16(INK4A) and p18(INK4C).","date":"1999","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10556039","citation_count":35,"is_preprint":false},{"pmid":"22997239","id":"PMC_22997239","title":"Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.","date":"2012","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/22997239","citation_count":33,"is_preprint":false},{"pmid":"9432125","id":"PMC_9432125","title":"Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma.","date":"1998","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/9432125","citation_count":29,"is_preprint":false},{"pmid":"29694893","id":"PMC_29694893","title":"SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29694893","citation_count":29,"is_preprint":false},{"pmid":"19401813","id":"PMC_19401813","title":"Expression of p18(INK4C) is down-regulated in human pituitary adenomas.","date":"2009","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19401813","citation_count":28,"is_preprint":false},{"pmid":"24167278","id":"PMC_24167278","title":"Gata3/Ruvbl2 complex regulates T helper 2 cell proliferation via repression of Cdkn2c expression.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24167278","citation_count":28,"is_preprint":false},{"pmid":"32090490","id":"PMC_32090490","title":"miR-21-5p promotes cell proliferation and G1/S transition in melanoma by targeting CDKN2C.","date":"2020","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/32090490","citation_count":27,"is_preprint":false},{"pmid":"21543644","id":"PMC_21543644","title":"Cyclin-dependent kinase inhibitor Cdkn2c regulates B cell homeostasis and function in the NZM2410-derived murine lupus susceptibility locus Sle2c1.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21543644","citation_count":27,"is_preprint":false},{"pmid":"12821941","id":"PMC_12821941","title":"Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12821941","citation_count":25,"is_preprint":false},{"pmid":"16953232","id":"PMC_16953232","title":"Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16953232","citation_count":25,"is_preprint":false},{"pmid":"23175770","id":"PMC_23175770","title":"Zebrafish dmrta2 regulates the expression of cdkn2c in spermatogenesis in the adult testis.","date":"2013","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/23175770","citation_count":24,"is_preprint":false},{"pmid":"17803708","id":"PMC_17803708","title":"Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours.","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17803708","citation_count":24,"is_preprint":false},{"pmid":"12668976","id":"PMC_12668976","title":"p18(INK4c) collaborates with other CDK-inhibitory proteins in the regenerating liver.","date":"2003","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12668976","citation_count":23,"is_preprint":false},{"pmid":"8519415","id":"PMC_8519415","title":"Molecular analysis of a family of cyclin-dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non-small cell lung cancers.","date":"1995","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/8519415","citation_count":23,"is_preprint":false},{"pmid":"17049078","id":"PMC_17049078","title":"Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression.","date":"2006","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/17049078","citation_count":23,"is_preprint":false},{"pmid":"22896639","id":"PMC_22896639","title":"Cyclin-dependent kinase inhibitor Cdkn2c deficiency promotes B1a cell expansion and autoimmunity in a mouse model of lupus.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22896639","citation_count":22,"is_preprint":false},{"pmid":"26985855","id":"PMC_26985855","title":"CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.","date":"2016","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/26985855","citation_count":21,"is_preprint":false},{"pmid":"15107819","id":"PMC_15107819","title":"Activation of protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c).","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15107819","citation_count":20,"is_preprint":false},{"pmid":"33014799","id":"PMC_33014799","title":"LINC00673 Represses CDKN2C and Promotes the Proliferation of Esophageal Squamous Cell Carcinoma Cells by EZH2-Mediated H3K27 Trimethylation.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33014799","citation_count":19,"is_preprint":false},{"pmid":"26681454","id":"PMC_26681454","title":"Discovery of novel INK4C small-molecule inhibitors to promote human and murine hematopoietic stem cell ex vivo expansion.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26681454","citation_count":19,"is_preprint":false},{"pmid":"16397248","id":"PMC_16397248","title":"Hematopoietic stem cells are not the direct target of spontaneous leukemic transformation in p18(INK4C)-null reconstituted mice.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16397248","citation_count":19,"is_preprint":false},{"pmid":"32483149","id":"PMC_32483149","title":"A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32483149","citation_count":18,"is_preprint":false},{"pmid":"19029828","id":"PMC_19029828","title":"Differential post-transcriptional regulation of two Ink4 proteins, p18 Ink4c and p19 Ink4d.","date":"2008","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/19029828","citation_count":17,"is_preprint":false},{"pmid":"17710155","id":"PMC_17710155","title":"Mutational analysis of p27 (CDKN1B) and p18 (CDKN2C) in sporadic pancreatic endocrine tumors argues against tumor-suppressor function.","date":"2007","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/17710155","citation_count":16,"is_preprint":false},{"pmid":"33015533","id":"PMC_33015533","title":"CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1-Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion.","date":"2020","source":"JCO precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33015533","citation_count":14,"is_preprint":false},{"pmid":"29334315","id":"PMC_29334315","title":"Interplay between p53 and Ink4c in spermatogenesis and fertility.","date":"2018","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/29334315","citation_count":13,"is_preprint":false},{"pmid":"29134609","id":"PMC_29134609","title":"Expression of p27Kip1 and p18Ink4c in human multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors.","date":"2017","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29134609","citation_count":13,"is_preprint":false},{"pmid":"11891212","id":"PMC_11891212","title":"Pituitary hyperplasia in glycoprotein hormone alpha subunit-, p18(INK4C)-, and p27(kip-1)-null mice: analysis of proteins influencing p27(kip-1) ubiquitin degradation.","date":"2002","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11891212","citation_count":13,"is_preprint":false},{"pmid":"35326705","id":"PMC_35326705","title":"CDK6 Degradation Is Counteracted by p16INK4A and p18INK4C in AML.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35326705","citation_count":12,"is_preprint":false},{"pmid":"18642058","id":"PMC_18642058","title":"Sodium butyrate-induced upregulation of p18( INK4C ) gene affects K562 cell G (0)/G (1) arrest and differentiation.","date":"2008","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18642058","citation_count":12,"is_preprint":false},{"pmid":"23896637","id":"PMC_23896637","title":"The negative cell cycle regulators, p27(Kip1), p18(Ink4c), and GSK-3, play critical role in maintaining quiescence of adult human pancreatic β-cells and restrict their ability to proliferate.","date":"2013","source":"Islets","url":"https://pubmed.ncbi.nlm.nih.gov/23896637","citation_count":12,"is_preprint":false},{"pmid":"34896253","id":"PMC_34896253","title":"CDKN2C expression in adipose tissue is reduced in type II diabetes and central obesity: impact on adipocyte differentiation and lipid storage?","date":"2021","source":"Translational research : the journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34896253","citation_count":11,"is_preprint":false},{"pmid":"22617107","id":"PMC_22617107","title":"Antitumor activity of cell-permeable p18(INK4c) with enhanced membrane and tissue penetration.","date":"2012","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22617107","citation_count":10,"is_preprint":false},{"pmid":"37733753","id":"PMC_37733753","title":"CBX8 promotes lung adenocarcinoma growth and metastasis through transcriptional repression of CDKN2C and SCEL.","date":"2023","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/37733753","citation_count":9,"is_preprint":false},{"pmid":"29066476","id":"PMC_29066476","title":"Role of CDKN2C Fluorescence In Situ Hybridization in the Management of Medullary Thyroid Carcinoma.","date":"2017","source":"Annals of clinical and laboratory science","url":"https://pubmed.ncbi.nlm.nih.gov/29066476","citation_count":9,"is_preprint":false},{"pmid":"31648931","id":"PMC_31648931","title":"Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma.","date":"2019","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/31648931","citation_count":9,"is_preprint":false},{"pmid":"26292318","id":"PMC_26292318","title":"A Conserved Gammaherpesvirus Cyclin Specifically Bypasses Host p18(INK4c) To Promote Reactivation from Latency.","date":"2015","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/26292318","citation_count":9,"is_preprint":false},{"pmid":"36334246","id":"PMC_36334246","title":"Novel germline variants of CDKN1B and CDKN2C identified during screening for familial primary hyperparathyroidism.","date":"2022","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36334246","citation_count":8,"is_preprint":false},{"pmid":"38849466","id":"PMC_38849466","title":"Oxidative modification of miR-30c promotes cardiac fibroblast proliferation via CDKN2C mismatch.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38849466","citation_count":8,"is_preprint":false},{"pmid":"23049777","id":"PMC_23049777","title":"An opposite effect of the CDK inhibitor, p18(INK4c) on embryonic stem cells compared with tumor and adult stem cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23049777","citation_count":8,"is_preprint":false},{"pmid":"21112821","id":"PMC_21112821","title":"N-Myc is a downstream target of RET signaling and is required for transcriptional regulation of p18(Ink4c) by the transforming mutant RET(C634R).","date":"2010","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21112821","citation_count":7,"is_preprint":false},{"pmid":"29298882","id":"PMC_29298882","title":"Host Tumor Suppressor p18INK4c Functions as a Potent Cell-Intrinsic Inhibitor of Murine Gammaherpesvirus 68 Reactivation and Pathogenesis.","date":"2018","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/29298882","citation_count":5,"is_preprint":false},{"pmid":"23698709","id":"PMC_23698709","title":"The combination of two Sle2 lupus-susceptibility loci and Cdkn2c deficiency leads to T-cell-mediated pathology in B6.Fas(lpr) mice.","date":"2013","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/23698709","citation_count":5,"is_preprint":false},{"pmid":"17099725","id":"PMC_17099725","title":"Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17099725","citation_count":5,"is_preprint":false},{"pmid":"27888400","id":"PMC_27888400","title":"Repression of CDKN2C caused by PML/RARα binding promotes the proliferation and differentiation block in acute promyelocytic leukemia.","date":"2016","source":"Frontiers of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27888400","citation_count":4,"is_preprint":false},{"pmid":"24714825","id":"PMC_24714825","title":"Deletion of p18(INK4c) aggravates cisplatin-induced acute kidney injury.","date":"2014","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24714825","citation_count":3,"is_preprint":false},{"pmid":"27287689","id":"PMC_27287689","title":"A novel lymphoid progenitor cell population (LSK(low)) is restricted by p18(INK4c).","date":"2016","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/27287689","citation_count":2,"is_preprint":false},{"pmid":"15847943","id":"PMC_15847943","title":"Lack of effect of extremely low frequency electromagnetic fields on cyclin-dependent kinase 4 inhibitor gene p18(INK4C) in electric energy workers.","date":"2005","source":"Archives of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/15847943","citation_count":2,"is_preprint":false},{"pmid":"39426133","id":"PMC_39426133","title":"Enhancing radiosensitivity in osteosarcoma via CDKN2C overexpression: A mechanism involving G1 phase arrest mediated by inhibition of CDK4 expression and Thr172 phosphorylation.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39426133","citation_count":1,"is_preprint":false},{"pmid":"12796810","id":"PMC_12796810","title":"The effects of inhibiting P18(INK4C) expression on the invasion of gastric adenocarcinoma cell line.","date":"2003","source":"Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/12796810","citation_count":1,"is_preprint":false},{"pmid":"40340925","id":"PMC_40340925","title":"A Case of CDKN2C/CIC Null Epithelioid Leiomyosarcoma With a Low-grade Component Indistinguishable From Leiomyoma.","date":"2025","source":"International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/40340925","citation_count":1,"is_preprint":false},{"pmid":"40680849","id":"PMC_40680849","title":"A Genomic Alteration in GATA3 Affects Treatment Responses With a CDK4/6 Inhibitor Collaborating With p18INK4C Expression in Advanced Breast Carcinoma.","date":"2025","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/40680849","citation_count":1,"is_preprint":false},{"pmid":"16989285","id":"PMC_16989285","title":"Long-term engraftment of p18(INK4C)-deficient hematopoietic stem cells is enhanced in the sublethally-irradiated recipients.","date":"2006","source":"Science in China. Series C, Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16989285","citation_count":1,"is_preprint":false},{"pmid":"40597397","id":"PMC_40597397","title":"Deletion of p18INK4c enhances both osteogenesis and hematopoietic supportive capacity of bone marrow mesenchymal stromal cells.","date":"2025","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/40597397","citation_count":0,"is_preprint":false},{"pmid":"42049330","id":"PMC_42049330","title":"Ubiquitin Ligase RNF149 Promotes Head and Neck Cancer Growth via Downregulation of CDKN2C.","date":"2026","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/42049330","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.07.06.663389","title":"eRNAs Modulate mRNA Stability and Translation Efficiency to Bridge Transcriptional and Post-transcriptional Gene Regulation","date":"2025-07-06","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.06.663389","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49001,"output_tokens":8424,"usd":0.136682,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18038,"output_tokens":6679,"usd":0.128582,"stage2_stop_reason":"end_turn"},"total_usd":0.265264,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"p18(INK4c) associates with CDK6 upon IL-6 stimulation in B lymphoblastoid cells, suppressing CDK6 activity and thereby inhibiting pRb phosphorylation, leading to cell cycle arrest coupled to terminal B cell differentiation.\",\n      \"method\": \"Co-immunoprecipitation, Western blot, overexpression in lymphoblastoid cells, flow cytometry\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal association demonstrated by Co-IP, functional overexpression rescue experiment, replicated in multiple cell contexts\",\n      \"pmids\": [\"9052836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"p18(INK4c) and p27(Kip1) mediate two genetically separable pathways to suppress pituitary tumorigenesis; mice lacking both develop pituitary adenomas with near-complete penetrance by 3 months, while single knockouts develop adenomas more slowly, indicating non-redundant collaborative tumor suppression likely through controlling Rb function.\",\n      \"method\": \"Genetic epistasis — single and double knockout mouse models, histopathology, proliferation assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in mouse models with clear double-mutant phenotypic readout, replicated across multiple groups\",\n      \"pmids\": [\"9744866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"p18(INK4C) and p16(INK4A) share the ankyrin-repeat fold but differ in conformational stability: p18 has a subset of very slowly exchanging amide protons (especially in the fourth ankyrin repeat region) indicating greater kinetic stability than p16 and p15, which correlates with lower aggregation tendency.\",\n      \"method\": \"NMR (H/2H exchange, heteronuclear NOE), chemical denaturation\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal NMR methods with functional relevance (aggregation), single lab\",\n      \"pmids\": [\"10556039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"p18(INK4c) cooperates with p27(Kip1) to inhibit cyclin E-CDK2 and CDK4/6 in progestin-mediated cell cycle arrest: p27 directly inhibits cyclin E-CDK2 whereas p18 binds CDK4/CDK6 and, through redistribution of CDK inhibitor complexes, secondarily reduces cyclin E-CDK2 activity.\",\n      \"method\": \"In vitro kinase assay with recombinant His6-p27 and recombinant p18(INK4c), co-immunoprecipitation, gel filtration chromatography, Western blot\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with recombinant proteins plus in-cell validation by Co-IP, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"10713180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Combined loss of p18(Ink4c) and p19(Ink4d) in male mice causes infertility by impairing mitotic exit of spermatogonia and blocking meiotic maturation of spermatocytes; loss of p18 alone causes Leydig cell hyperplasia with reduced testosterone production independent of LH levels.\",\n      \"method\": \"Single and double knockout mouse genetics, histopathology, hormone assays (LH, FSH, testosterone), cell cycle analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — double-mutant genetic epistasis with defined cellular phenotype and hormonal readouts, clear loss-of-function design\",\n      \"pmids\": [\"11287627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"p18(INK4c) is required within B cells for terminal plasma cell differentiation and cell cycle arrest; p18-deficient mice show B cell hyperproliferation in germinal centers despite normal class switch, hypermutation, and plasmacytoid differentiation, but severely reduced antibody secretion, placing p18 as a requisite CDK6 inhibitor for functional plasma cell generation.\",\n      \"method\": \"Conditional/germline knockout mouse model, immunization, ELISA for antibody titers, histology, flow cytometry\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout with multiple cellular and functional readouts; replicates and extends the earlier IL-6/B-cell finding\",\n      \"pmids\": [\"12196289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"p18(INK4c) upregulation by STI571 is required for G1 arrest in ETV6/ARG-expressing leukemia cells; antisense knockdown of Ink4c abrogates STI571-induced growth inhibition, demonstrating that p18 is a downstream effector of ARG kinase suppression.\",\n      \"method\": \"Antisense oligonucleotide knockdown, cell cycle analysis (flow cytometry), Western blot, cell fractionation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — antisense knockdown with direct functional rescue, single lab, single cell line\",\n      \"pmids\": [\"12821941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"p18(INK4c) collaborates with p21(CIP1) to control G1 timing and with p27(KIP1) to limit hepatocyte DNA synthesis after partial hepatectomy; double knockouts of p18/p21 show earlier CDK activation and earlier G1 exit, while p18/p27 double knockouts show elevated hepatocyte proliferation at 48 hours.\",\n      \"method\": \"Single and double knockout mouse models, partial hepatectomy, BrdU/PCNA labeling, Western blot for cell cycle proteins\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — double-mutant epistasis with defined cellular readouts, single lab\",\n      \"pmids\": [\"12668976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In p18(INK4c)-positive hepatocellular carcinomas, p18 preferentially associates with CDK4 rather than CDK6, leading to reduced CDK4 kinase activity and less pRb phosphorylation at Ser780 compared with p18-negative tumors.\",\n      \"method\": \"Co-immunoprecipitation, in vitro CDK4/CDK6 kinase assay, Western blot with phospho-Rb antibody, immunohistochemistry\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP combined with kinase activity assay in tumor tissue, single lab\",\n      \"pmids\": [\"15349907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PKC activation by TPA suppresses p18(INK4c) expression at the promoter level in an AP-1-independent manner, and siRNA knockdown of p18 enhances cancer cell growth, demonstrating that p18 is a critical PKC-regulated growth-inhibitory target.\",\n      \"method\": \"siRNA knockdown, promoter reporter assays, PKC inhibitor (Ro 31-8425), dominant-negative c-Jun expression, cell growth assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA plus pharmacological inhibition plus promoter assay, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"15107819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Ink4c is haploinsufficient for tumor suppression when combined with Patched (Ptc1) heterozygosity; tumors in Ink4c+/-/Ptc1+/- mice retain wild-type Ink4c but lose wild-type Ptc1, and methylation of INK4C is found in 4/23 human medulloblastomas with absent p18 protein in 14/73 cases, placing Ink4c in the Shh pathway for cerebellar granule cell cycle exit.\",\n      \"method\": \"Compound heterozygous mouse genetics, LOH analysis, methylation analysis, immunohistochemistry, in situ hybridization\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with allele-specific LOH analysis, multiple orthogonal methods including human tumor validation\",\n      \"pmids\": [\"16260494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Loss of p18(INK4c) enhances long-term hematopoietic stem cell self-renewal and engraftment over serial transplants; p18-null HSCs resist exhaustion and maintain multilineage potential for >3 years of serial transfers, with effects shown to antagonize p21-driven senescence at the stem cell level.\",\n      \"method\": \"Serial bone marrow transplantation, competitive repopulation assay, flow cytometry, long-term culture\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rigorous long-term in vivo functional assay over 3+ years, multiple rounds of transplantation\",\n      \"pmids\": [\"16234365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MEN2A-specific RET(C634R) simultaneously represses p18/Ink4c and p27 mRNA levels while elevating cyclin D1, requiring functional MAPK signaling; RET2A-dependent p18 repression alone is sufficient to increase proliferation, and MEN2A adrenal tumors recapitulate this expression profile in vivo.\",\n      \"method\": \"Inducible RET2A expression, RT-PCR, Western blot, MEK inhibitor treatment, cyclin D1/p18/p27 quantification in primary tumors\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible system with pharmacological pathway dissection and in vivo tumor validation, single lab\",\n      \"pmids\": [\"16953232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"p18(Ink4c) and Pten constrain a positive regulatory loop: deletion of p18 (or CDK4 overexpression, or Rb inactivation) activates Akt/PKB, but this is recessive to PTEN reduction, indicating that CDK-dependent Rb pathway outputs feed back to the PI3K/Akt pathway.\",\n      \"method\": \"Double-mutant mouse models (p18-/-, Pten+/-), Western blot for phospho-Akt, tumor analysis, LOH at Pten locus\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with biochemical readout of Akt activation, single lab\",\n      \"pmids\": [\"16738322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"p18(Ink4c) protein stability is regulated by polyubiquitination at preferred lysines K46 and K112; binding to CDK4 or CDK6 (active or inactive) inhibits polyubiquitination and stabilizes p18, while cyclin D1 competes with p18 for CDK binding and accelerates p18 degradation. Substitution of multiple lysines triggers misfolding and accelerates degradation.\",\n      \"method\": \"In vitro ubiquitination assay, site-directed mutagenesis (lysine-to-arginine substitutions), co-expression with CDKs and cyclin D1, half-life measurement\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro biochemical reconstitution combined with mutagenesis and half-life measurements; multiple mechanistic conclusions supported\",\n      \"pmids\": [\"19029828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Lentiviral reconstitution of p18(INK4c) at physiologic levels in p18-deficient GBM cells induces senescence-like G1 arrest, while p18-proficient GBM cells are unaffected, establishing p18 as a functional tumor suppressor whose loss drives CDK-mediated cell cycle progression in GBM.\",\n      \"method\": \"Lentiviral reconstitution, cell cycle analysis (flow cytometry), immunohistochemistry on primary GBM tumors\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reconstitution experiment with isogenic p18-deficient vs. -proficient controls, single lab\",\n      \"pmids\": [\"18381405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"NaBu-induced p18(INK4c) upregulation requires intact Sp1 binding sites in the p18 promoter; NaBu causes histone H3/H4 hyperacetylation at the endogenous p18 promoter and enhanced Sp1 binding in vivo, and overexpression of p18 alone induces G0/G1 arrest and partial erythroid differentiation in K562 cells.\",\n      \"method\": \"Promoter reporter assays with Sp1 cluster mutations, chromatin immunoprecipitation (ChIP), flow cytometry, overexpression\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus promoter mutagenesis plus functional overexpression, single lab\",\n      \"pmids\": [\"18642058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GATA3 directly binds to and represses INK4C transcription; loss of p18(INK4c) in mice causes spontaneous ER-positive luminal mammary tumors, and GATA3-driven expansion of luminal progenitor cells is mechanistically linked to p18 repression.\",\n      \"method\": \"ChIP demonstrating GATA3 binding at INK4C locus, transgenic/knockout mouse models, gene expression analysis, luciferase reporter\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct ChIP plus loss-of-function mouse genetics plus mechanistic reporter assay, consistent with independent in vitro and in vivo data\",\n      \"pmids\": [\"19411068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RET2A signaling induces N-Myc via MAPK; N-Myc then binds an initiator consensus element in the p18(Ink4c) promoter to repress p18 transcription; loss of N-Myc induction prevents RET2A-mediated p18 repression and hyperproliferation.\",\n      \"method\": \"Promoter ChIP for N-Myc binding, siRNA/dominant-negative N-Myc, RT-PCR, promoter reporter assay, MEK inhibitor\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus promoter reporter plus knockdown, single lab\",\n      \"pmids\": [\"21112821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A reduced-expression NZB allele of Cdkn2c (due to an SNP in the promoter) causes defective G1 arrest in splenic B cells and increased proliferation of peritoneal B1a cells, mapping CDKN2C as the functional gene within the Sle2c1 lupus susceptibility locus responsible for B1a cell expansion.\",\n      \"method\": \"Genetic mapping, promoter SNP identification, B cell proliferation assay, cell cycle analysis, co-segregation analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic mapping combined with functional cell cycle assay, single lab\",\n      \"pmids\": [\"21543644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BRAF(V600E)/NRAS(G12D)-driven MAPK signaling promotes G1 melanoma cell proliferation through AP-1 (c-Jun)-mediated transcriptional repression of CDKN2C; dominant-negative AP-1 restores CDKN2C expression and pharmacological CDK2/4 inhibition augments effects of BRAF/MEK inhibitors in vitro and in vivo.\",\n      \"method\": \"Dominant-negative c-Jun expression, Western blot, flow cytometry, cell proliferation assay, xenograft tumor model\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative approach with in vitro and xenograft validation, single lab\",\n      \"pmids\": [\"22997239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Gata3 associates with Ruvbl2 and, as a complex, directly binds the Cdkn2c locus to repress its transcription in Th2 cells; Gata3-dependent repression of Cdkn2c facilitates Th2 cell proliferation, and knockdown of Cdkn2c rescues the proliferation defect in Gata3-deficient Th2 cells.\",\n      \"method\": \"Co-immunoprecipitation of Gata3/Ruvbl2 complex, ChIP at Cdkn2c locus, Ruvbl2 knockdown, Cdkn2c knockdown rescue experiment, airway inflammation model\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus ChIP plus epistatic knockdown rescue, multiple orthogonal methods in one study\",\n      \"pmids\": [\"24167278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"p18(Ink4c) interacts with CDK4 in adult human pancreatic β-cells (detected by co-immunoprecipitation), and p18 protein localizes predominantly to the cytosol while p27(Kip1) localizes to nuclei, both contributing to maintenance of β-cell quiescence.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence/confocal microscopy, subcellular fractionation, BrdU incorporation assay\",\n      \"journal\": \"Islets\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP and confocal localization, functional BrdU assay, single lab, single paper\",\n      \"pmids\": [\"23896637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Small-molecule inhibitors of p18(INK4c) identified by in silico structure-based screening specifically block p18 activity and promote ex vivo expansion of functional murine and human hematopoietic stem cells; lead compound XIE18-6 analogue (compound 40) expands HSCs with ED50 = 5.21 nM without cytotoxicity.\",\n      \"method\": \"In silico 3D screening based on p18 structure, SAR synthesis, HSC expansion assay (long-term culture), single-cell analysis, competitive repopulation in mice\",\n      \"journal\": \"Nature communications / Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — structure-based inhibitor design with in vitro and in vivo HSC functional validation, two independent publications from same group\",\n      \"pmids\": [\"25692908\", \"26681454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"p18(INK4c) functions as a cell-intrinsic inhibitor of gammaherpesvirus reactivation from latency; the viral cyclin specifically bypasses p18 to enable reactivation, and genetic ablation of p18 alone is sufficient to render the viral cyclin dispensable for reactivation from latency.\",\n      \"method\": \"Knockout mouse genetics (p18-/-, p27-/- single and double knockouts), recombinant virus with p18 knock-in (p18KI), viral reactivation assay, BAFF cytokine treatment\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with recombinant virus knock-in, multiple genetic backgrounds tested, functional viral reactivation readout\",\n      \"pmids\": [\"26292318\", \"29298882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"p18(INK4c) and p57(Kip2) nuclear localization is associated with antiproliferative TKI activity in CML cells; TKI treatment reduces nuclear p18 in CML leukemic stem cells, suggesting that subcellular redistribution of p18 contributes to quiescence maintenance after TKI treatment.\",\n      \"method\": \"Subcellular fractionation, immunofluorescence, cell cycle analysis in CML cell lines and primary CD34+CD38-lin- LSCs and HSCs\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — localization by immunofluorescence/fractionation without direct functional manipulation of p18 localization, single lab\",\n      \"pmids\": [\"26985855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PML/RARα directly binds the CDKN2C promoter and represses its transcription in a dose-dependent manner; all-trans retinoic acid releases PML/RARα from chromatin and restores CDKN2C expression; ectopic CDKN2C expression induces G0/G1 arrest and partial differentiation in APL NB4 cells.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP-qPCR), luciferase reporter assay, ATRA treatment, CDKN2C overexpression, flow cytometry\",\n      \"journal\": \"Frontiers of medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP combined with promoter reporter and functional overexpression, single lab\",\n      \"pmids\": [\"27888400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SETDB2 (a protein lysine methyltransferase) silences CDKN2C through histone H3K9 trimethylation at its locus; SETDB2 is a direct E2A-PBX1 target gene, establishing an oncogenic axis E2A-PBX1→SETDB2→H3K9me3 at CDKN2C→CDKN2C repression in pre-BCR+ ALL.\",\n      \"method\": \"ChIP for H3K9me3 at CDKN2C locus, SETDB2 knockdown, E2A-PBX1 ChIP, gene expression analysis, in vitro and in vivo leukemia maintenance assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP demonstrating H3K9me3 enrichment plus epistatic knockdown experiments with in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"29694893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CDKN2C induces G1 arrest by inhibiting CDK4/6, which is required for efficient HBV replication; CDKN2C is overexpressed in highly permissive hepatocytes and HBV-infected patients, and its loss reduces viral transcription enhancer activity, identifying CDKN2C-dependent G1 arrest as a proviral mechanism.\",\n      \"method\": \"Genome-wide gain-of-function screen, validation in primary human hepatocytes, gene knockdown/overexpression, viral replication assay, transcription enhancer reporter\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional screen validation in primary hepatocytes with mechanistic reporter assay, single lab\",\n      \"pmids\": [\"32483149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LINC00673 lncRNA represses CDKN2C expression through EZH2-mediated H3K27 trimethylation at the CDKN2C promoter; EZH2 inhibition or LINC00673 knockdown increases CDKN2C protein, and CDKN2C depletion restores G1/S progression in cells with reduced LINC00673.\",\n      \"method\": \"ChIP for H3K27me3 at CDKN2C promoter, EZH2 inhibitor treatment, siRNA knockdown, Western blot, flow cytometry\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus pharmacological inhibition plus epistatic knockdown, single lab\",\n      \"pmids\": [\"33014799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"p18INK4C protects CDK6 from degradation by the CDK6-specific PROTAC BSJ-03-123: CDK6 complexes containing p18INK4C (or p16INK4A) are shielded from PROTAC-mediated degradation; elevated INK4 levels in KMT2A-MLLT3+ AML cells correlate with resistance to CDK6 degradation.\",\n      \"method\": \"CDK6 degrader (PROTAC BSJ-03-123) treatment, Western blot, co-immunoprecipitation, proliferation assay in AML cell lines\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP showing complex protection from degradation with pharmacological PROTAC, single lab\",\n      \"pmids\": [\"35326705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CBX8 directly binds to the CDKN2C promoter and establishes H2AK119 ubiquitination to repress CDKN2C transcription in lung adenocarcinoma; CBX8 depletion reduces H2AK119ub enrichment at the CDKN2C promoter, and CDKN2C knockdown rescues the growth/invasion suppression caused by CBX8 depletion.\",\n      \"method\": \"ChIP assay for CBX8 binding and H2AK119ub at CDKN2C promoter, CBX8 knockdown/overexpression, CDKN2C knockdown rescue experiment, RNA sequencing\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus epistatic rescue experiment, single lab\",\n      \"pmids\": [\"37733753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CDKN2C overexpression enhances radiosensitivity of osteosarcoma cells by inducing G1 arrest through suppression of CDK4 expression and Thr172 phosphorylation (but not CDK6 or Cyclin D1 expression), leading to reduced pRb Ser807/811 phosphorylation and increased apoptosis (BAX, Caspase-3) when combined with irradiation.\",\n      \"method\": \"Lentiviral CDKN2C overexpression, Western blot for CDK4 phosphorylation and pRb phosphorylation, flow cytometry cell cycle analysis, xenograft mouse model, apoptosis assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — overexpression with mechanistic Western blot readouts and in vivo validation, single lab\",\n      \"pmids\": [\"39426133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Oxidative modification of miR-30c at positions 4 and 5 (G→O8G, producing 4,5-oxo-miR-30c) causes mismatch recognition of CDKN2C mRNA, reducing CDKN2C protein levels and promoting cardiac fibroblast proliferation; unmodified miR-30c does not target CDKN2C in this manner.\",\n      \"method\": \"Luciferase reporter assay, miRNA immunoprecipitation with O8G antibody, cardiac fibrosis animal models (Ang II, ischemia-reperfusion), overexpression of oxidized miR-30c mimics\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase validation of mismatch targeting plus in vivo animal models, single lab\",\n      \"pmids\": [\"38849466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RNF149, a RING finger ubiquitin ligase, ubiquitinates CDKN2C protein in head and neck squamous cell carcinoma; RNF149 and CDKN2C show an inverse expression correlation in tissue arrays, and RNF149 knockdown reduces HNSC proliferation while altering CDK inhibitor sensitivity.\",\n      \"method\": \"Proximity ligation assay, immunoprecipitation, gene knockdown, proliferation/cell cycle assay, 3D assay, tissue array immunohistochemistry\",\n      \"journal\": \"Anticancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — PLA and Co-IP suggest ubiquitination interaction, single lab, no direct ubiquitin transfer assay shown in abstract\",\n      \"pmids\": [\"42049330\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CDKN2C/p18(INK4c) is an ankyrin-repeat CDK inhibitor that binds CDK4 and CDK6 to prevent their activation by D-type cyclins, thereby maintaining Rb in its hypophosphorylated growth-suppressive state; its stability is controlled by polyubiquitination at K46/K112 that is inhibited by CDK binding and accelerated by competition with cyclin D1, and its transcription is regulated by multiple epigenetic mechanisms including GATA3-direct binding, EZH2-mediated H3K27me3 (via LINC00673), CBX8-mediated H2AK119ub, SETDB2-mediated H3K9me3 (downstream of E2A-PBX1), PML/RARα direct promoter binding, N-Myc (downstream of RET/MAPK), and Sp1 acetylation-dependent activation, placing it as a nodal tumor suppressor required for plasma cell differentiation, hematopoietic stem cell self-renewal restraint, spermatogenesis, mammary luminal progenitor control, and cell-intrinsic suppression of gammaherpesvirus reactivation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CDKN2C/p18(INK4c) is an ankyrin-repeat CDK inhibitor that enforces G1 cell cycle exit by binding CDK4 and CDK6 to suppress their kinase activity, thereby maintaining Rb in its hypophosphorylated, growth-suppressive state across diverse differentiating tissues [#0, #8, #32]. It engages CDK6 upon IL-6 stimulation to couple cell cycle arrest to terminal B cell/plasma cell differentiation [#0, #5], and cooperates with the Cip/Kip inhibitors p27 and p21 in genetically separable pathways that restrain proliferation in the pituitary, liver, and other tissues, in part by redistributing CDK-inhibitor complexes to secondarily lower cyclin E-CDK2 activity [#1, #3, #7]. Through this CDK4/6-Rb axis p18 acts as a nodal tumor suppressor whose loss or repression drives proliferation and tumorigenesis: it restrains hematopoietic stem cell self-renewal [#11], limits mammary luminal progenitor expansion [#17], and is haploinsufficient within the Shh/Patched pathway in medulloblastoma [#10]. Its dosage is set at two levels. Post-translationally, p18 stability is governed by polyubiquitination at preferred lysines K46 and K112; CDK4/6 binding shields p18 from ubiquitination and stabilizes it, while cyclin D1 competes for CDK binding and accelerates p18 turnover [#14]. Transcriptionally, p18 is repressed by a convergent set of factors and chromatin modifiers, including direct GATA3 binding (in complex with Ruvbl2) [#17, #21], oncogenic MAPK-driven repression via AP-1/c-Jun and N-Myc [#18, #20], PML/RARα at the promoter [#26], and Polycomb/heterochromatin marks deposited by EZH2 (H3K27me3, via LINC00673), CBX8 (H2AK119ub), and SETDB2 (H3K9me3, downstream of E2A-PBX1) [#27, #29, #31]. p18 also functions as a cell-intrinsic restrictor of gammaherpesvirus reactivation, an activity specifically bypassed by the viral cyclin [#24].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that p18(INK4c) physically engages CDK6 and links cytokine signaling to cell cycle arrest, defining its core molecular activity in differentiation.\",\n      \"evidence\": \"Co-IP and overexpression in IL-6-stimulated B lymphoblastoid cells with pRb phosphorylation readout\",\n      \"pmids\": [\"9052836\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not distinguish CDK6 versus CDK4 preference in other contexts\", \"Endogenous regulation of p18 induction by IL-6 not mapped\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrated that p18 suppresses tumorigenesis through a pathway genetically separable from p27, showing it is a non-redundant in vivo tumor suppressor.\",\n      \"evidence\": \"Single and double knockout mouse genetics with pituitary adenoma histopathology\",\n      \"pmids\": [\"9744866\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of the p18/p27 division of labor at the CDK level not fully resolved here\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Resolved how p18 differs biophysically from related INK4 proteins, showing greater kinetic stability of its ankyrin-repeat fold.\",\n      \"evidence\": \"NMR H/2H exchange and chemical denaturation of p18 versus p16/p15\",\n      \"pmids\": [\"10556039\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conformational stability not directly tied to CDK-binding affinity or in-cell function\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Clarified that p18 cooperates with p27 not by directly inhibiting CDK2 but by redistributing inhibitor complexes, explaining secondary suppression of cyclin E-CDK2.\",\n      \"evidence\": \"In vitro kinase assays with recombinant proteins, Co-IP, and gel filtration in progestin-arrested cells\",\n      \"pmids\": [\"10713180\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative stoichiometry of complex redistribution in vivo not established\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Extended p18 function to germ cell and Leydig cell proliferation control, showing tissue-specific requirements in spermatogenesis.\",\n      \"evidence\": \"Single/double p18/p19 knockout mouse genetics with hormone assays and cell cycle analysis\",\n      \"pmids\": [\"11287627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CDK partner mediating the spermatogonial and Leydig phenotypes not pinpointed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed p18 is required cell-intrinsically in B cells for terminal plasma cell differentiation and antibody secretion, cementing its differentiation-arrest role.\",\n      \"evidence\": \"Knockout mouse immunization with ELISA antibody titers, histology, flow cytometry\",\n      \"pmids\": [\"12196289\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional trigger of p18 during plasma cell commitment not defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified p18 as a downstream effector of oncogenic kinase inhibition and as a collaborator with Cip/Kip inhibitors in regenerative proliferation, broadening its signaling context.\",\n      \"evidence\": \"Antisense knockdown in ETV6/ARG leukemia cells; p18/p21 and p18/p27 double-knockout partial hepatectomy models\",\n      \"pmids\": [\"12821941\", \"12668976\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-cell-line antisense without reciprocal validation\", \"Direct vs indirect link between ARG kinase and p18 transcription unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Established context-dependent CDK partner choice and the first promoter-level repression mechanism, showing p18 preferentially binds CDK4 in HCC and is suppressed by PKC signaling.\",\n      \"evidence\": \"Co-IP plus CDK4/CDK6 kinase assays in HCC tumors; siRNA, promoter reporters, and PKC inhibition in cancer cells\",\n      \"pmids\": [\"15349907\", \"15107819\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The PKC-responsive promoter element/transcription factor not identified\", \"AP-1-independence mechanism left open\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined p18 as a dosage-sensitive tumor suppressor within the Shh pathway and as a restraint on hematopoietic stem cell self-renewal, revealing stem/progenitor roles.\",\n      \"evidence\": \"Ink4c+/-/Ptc1+/- compound genetics with LOH and human medulloblastoma methylation; serial bone marrow transplantation of p18-null HSCs\",\n      \"pmids\": [\"16260494\", \"16234365\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How p18 intersects Shh signaling molecularly not detailed\", \"Mechanism of p18/p21 antagonism in HSC senescence not resolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Connected oncogenic RET/MAPK and Rb-pathway output to p18 regulation, showing p18 repression is both an effector of and feedback node for proliferative signaling.\",\n      \"evidence\": \"Inducible RET2A with MEK inhibition and tumor profiling; p18/Pten double-mutant mice with phospho-Akt readouts\",\n      \"pmids\": [\"16953232\", \"16738322\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional mediator of RET-driven p18 repression not yet identified (resolved later by N-Myc)\", \"Mechanism of Rb-to-Akt feedback indirect\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined the post-translational control of p18 abundance and its functional sufficiency as a senescence-inducing tumor suppressor, and identified an Sp1/acetylation-dependent activation route.\",\n      \"evidence\": \"In vitro ubiquitination with K-to-R mutagenesis and half-life measurement; lentiviral reconstitution in GBM cells; ChIP and Sp1-site promoter mutagenesis in K562\",\n      \"pmids\": [\"19029828\", \"18381405\", \"18642058\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the physiological E3 ligase for K46/K112 ubiquitination not established\", \"Cofactor coupling Sp1 to acetylation not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified GATA3 as a direct transcriptional repressor of INK4C, mechanistically linking luminal progenitor expansion and ER+ mammary tumorigenesis to p18 loss.\",\n      \"evidence\": \"ChIP, luciferase reporter, and loss-of-function mouse genetics in mammary tissue\",\n      \"pmids\": [\"19411068\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactor requirement for GATA3 repression not yet defined (later linked to Ruvbl2)\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Pinpointed N-Myc as the direct MAPK-induced repressor at the p18 promoter, completing the RET2A→MAPK→N-Myc→p18 repression axis.\",\n      \"evidence\": \"N-Myc promoter ChIP, dominant-negative/knockdown, reporter assays, and MEK inhibition\",\n      \"pmids\": [\"21112821\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab promoter study; generality across N-Myc-driven tumors untested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed a hypomorphic Cdkn2c promoter allele drives autoimmune B1a cell expansion, establishing p18 dosage as a disease-relevant determinant of B cell proliferation.\",\n      \"evidence\": \"Genetic mapping, promoter SNP identification, and B cell cell-cycle assays in the lupus Sle2c1 locus\",\n      \"pmids\": [\"21543644\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which the promoter SNP lowers expression not detailed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated AP-1/c-Jun-mediated CDKN2C repression downstream of BRAF/NRAS as a therapeutic vulnerability, supporting combined CDK and MAPK inhibition.\",\n      \"evidence\": \"Dominant-negative c-Jun, proliferation assays, and xenografts in melanoma\",\n      \"pmids\": [\"22997239\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct AP-1 binding at the CDKN2C promoter not shown here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed the GATA3-Ruvbl2 complex as the repressive machinery at Cdkn2c and extended this control to Th2 proliferation, and localized p18-CDK4 interaction to the cytosol in quiescent beta-cells.\",\n      \"evidence\": \"Gata3/Ruvbl2 Co-IP, ChIP, and Cdkn2c-knockdown rescue in Th2 cells; Co-IP and confocal fractionation in human beta-cells\",\n      \"pmids\": [\"24167278\", \"23896637\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional significance of cytosolic p18 localization not directly tested\", \"Whether GATA3-Ruvbl2 operates identically in mammary tissue untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Provided pharmacological proof that inhibiting p18 expands functional HSCs, validating p18 as a druggable restraint on stem cell self-renewal.\",\n      \"evidence\": \"Structure-based in silico screening, SAR, HSC expansion assays, and competitive repopulation\",\n      \"pmids\": [\"25692908\", \"26681454\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding mode of inhibitors to p18 and on-target specificity in vivo not fully resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established p18 as a cell-intrinsic restrictor of gammaherpesvirus reactivation, with a viral cyclin specifically bypassing it, and identified additional epigenetic repressors and a localization correlate in leukemia.\",\n      \"evidence\": \"p18 knockout/knock-in recombinant virus reactivation assays; PML/RARα ChIP and reporter with ATRA in APL; p18 immunofluorescence/fractionation in CML LSCs\",\n      \"pmids\": [\"26292318\", \"29298882\", \"27888400\", \"26985855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How p18 restricts reactivation mechanistically beyond CDK inhibition not defined\", \"CML localization study lacks direct functional manipulation\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the E2A-PBX1→SETDB2→H3K9me3 axis silencing CDKN2C, identifying heterochromatin-mediated repression as a leukemia maintenance mechanism.\",\n      \"evidence\": \"H3K9me3 and E2A-PBX1 ChIP, SETDB2 knockdown, and in vivo leukemia maintenance assays in pre-BCR+ ALL\",\n      \"pmids\": [\"29694893\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other INK4 loci are co-regulated by this axis not addressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Expanded the repressive epigenetic repertoire (EZH2/H3K27me3 via LINC00673) and uncovered a proviral role in which CDKN2C-driven G1 arrest supports HBV replication.\",\n      \"evidence\": \"H3K27me3 ChIP, EZH2 inhibition, siRNA in cancer cells; genome-wide gain-of-function screen and viral replication assays in primary hepatocytes\",\n      \"pmids\": [\"33014799\", \"32483149\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link between G1 arrest and HBV enhancer activity incompletely defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed INK4 binding shields CDK6 from targeted degradation, revealing p18 levels as a determinant of CDK6-PROTAC resistance.\",\n      \"evidence\": \"CDK6 PROTAC treatment, Co-IP, and proliferation assays in AML cell lines\",\n      \"pmids\": [\"35326705\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of degrader shielding not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Added CBX8/H2AK119ub as a Polycomb repressor of CDKN2C driving lung adenocarcinoma growth, reinforcing the epigenetic-silencing theme.\",\n      \"evidence\": \"CBX8 and H2AK119ub ChIP, knockdown/overexpression, and CDKN2C-knockdown rescue with RNA-seq\",\n      \"pmids\": [\"37733753\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interplay among the multiple repressive marks at CDKN2C not integrated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated CDKN2C confers radiosensitivity via CDK4-Thr172/pRb suppression and identified oxidized miR-30c as a post-transcriptional repressor, broadening the regulatory and therapeutic landscape.\",\n      \"evidence\": \"Lentiviral overexpression with phospho-CDK4/pRb readouts and xenografts in osteosarcoma; luciferase and O8G miRNA IP in cardiac fibrosis models\",\n      \"pmids\": [\"39426133\", \"38849466\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CDK4-selective effect generalizes beyond osteosarcoma untested\", \"Endogenous prevalence of oxidized miR-30c targeting CDKN2C in human disease unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Proposed RNF149 as a ubiquitin ligase acting on CDKN2C in HNSC, addressing which E3 controls p18 turnover.\",\n      \"evidence\": \"Proximity ligation assay, Co-IP, knockdown, and tissue arrays in head and neck squamous carcinoma\",\n      \"pmids\": [\"42049330\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No direct ubiquitin transfer assay demonstrating RNF149 catalyzes p18 ubiquitination\", \"Single lab without reciprocal in vivo validation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The physiological E3 ligase(s) executing the K46/K112 polyubiquitination that sets p18 half-life, and how the many transcriptional/epigenetic repressors are coordinated in a given lineage, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No validated endogenous E3 ligase for K46/K112 ubiquitination\", \"No structural model of the p18-CDK4/6 complex described in the corpus\", \"Combinatorial logic of GATA3, Polycomb, SETDB2, and MAPK-driven repressors not integrated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 3, 8, 32]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 3, 14, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [22]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 3, 8, 32]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 5, 11, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 10, 15, 17, 20, 27, 31]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CDK4\", \"CDK6\", \"CCND1\", \"CDKN1B\", \"GATA3\", \"RUVBL2\", \"RNF149\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}